Targeting Targeted Therapy
Mark R. Green · New England Journal of Medicine · 2004
The emergence of effective cancer chemotherapy is one of the major medical advances of the second half of the 20th century. In certain neoplasms — such as gestational choriocarcinoma, childhood acute lymphoblastic leukemia, and subgroups of Hodgkin's disease and non-Hodgkin's lymphoma — chemotherapy is often curative, and the promise of long-term survival makes therapy well worth the risk of adverse effects and the financial costs. Moreover, adjuvant chemotherapy for breast, colon, or lung cancer can augment the survival benefit afforded by surgical management. Even in patients with advanced solid tumors or recurrences despite surgery, chemotherapy can offer lengthened survival of . . .
Cited by 149 works. doi:10.1056/nejme048101
Authors
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
- Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
- Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
- The multifocality of bronchioloalveolar lung carcinoma: evidence and implications of a multiclonal origin.